Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

AGM Notification

19 Nov 2024 07:00

RNS Number : 6600M
Beximco Pharmaceuticals Ltd
19 November 2024
 

19 November 2024

 

BEXIMCO PHARMACEUTICALS LIMITED

 

AGM Notification

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the forty-eighth Annual General Meeting of Shareholders (AGM) of Beximco Pharma will be held on Sunday, the 29th December, 2024 at 10.30 am Bangladesh time under the Virtual Platform through https://bxpharma.bdvirtualagm.com to transact the following business:

 

AGENDA

 

ORDINARY BUSINESS:

 

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30th June, 2024 together with reports of the Auditors and the Directors thereon.

2. To declare 40% cash dividend as recommended by the Board of Directors.

3. To elect Directors.

4. To approve the appointment of Managing Director.

5. To approve the re-appointment of Independent Director.

6. To appoint Statutory Auditors for the year 2024-25 and to fix their remuneration.

7. To appoint Corporate Governance Compliance Auditors for the year 2024-25 and to fix their remuneration.

 

SPECIAL BUSINESS:

 

To pass Special Resolutions to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" as per the provision of the Companies Act, 1994 (as amended in 2020) and to effect the change of the name in the relevant Clauses of the Memorandum and Articles of Association of the Company.

 

The draft of the Special Resolutions proposed to be passed is given below:

 

"Resolved that the name of the Company be changed from Beximco Pharmaceuticals Limited to Beximco Pharmaceuticals PLC and the new name of the Company be incorporated in the Memorandum and Articles of Association of the Company and an amended copy of the Memorandum and Articles of Association of the Company be and is hereby adopted and the same be filed with the Registrar of Joint Stock Companies, Dhaka, Bangladesh for record."

 

Dated: November 18, 2024

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

 

 

NOTES:

(1) The Shareholders whose names appear in the Share Register of the Company or in the Depository Register on the record date i.e. 25 November, 2024 will be entitled to receive the dividend and to attend the Annual General Meeting.

 

(2) A Member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Share Department of the Company at BEL Tower, Level-2, 19 Dhanmondi, Road No.1, Dhaka-1205, no later than 48 hours before the time fixed for the meeting.

 

(3) Annual Report for the year 2023-24 will be sent through e-mail address of the valued Shareholders and will be available in the Website of the Company at: www.beximcopharma.com.

 

(4) The valued Shareholders will join the Virtual AGM through the Link https://bxpharma.bdvirtualagm.com. The Shareholders will be able to submit their questions/comments and vote electronically 24 (Twenty-four) hours before commencement of the AGM and also during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as proof by visiting the said Link.

 

(5) We encourage the Shareholders to login into the system prior to the meeting. Please allow ample time to login and establish your connectivity. For any IT related guidance, Shareholders may contact vide email : monir@beximco.net or mazibur@beximco.net.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUWVORSKUAAAA
Date   Source Headline
30th Jan 20237:00 amRNSHalf Year Results 2022-23
19th Jan 20237:00 amRNSPayment of Cash Dividend
23rd Dec 20227:00 amRNSAnnual General Meeting Statement
29th Nov 20222:06 pmRNSSecond Price Monitoring Extn
29th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSAGM Notification
11th Nov 20227:00 amRNSFinancial Results for the First Quarter
8th Nov 20227:00 amRNSResults for the 12-month period ended 30 June 2022
28th Oct 20227:00 amRNSNotification of Preliminary Results and AGM
28th Apr 20227:00 amRNSQ3 Financial Results
1st Apr 20227:00 amRNSSanofi Bangladesh Ltd. renamed Synovia Pharma PLC
17th Mar 20222:30 pmRNSMPP sub-license for Pfizer’s COVID-19 treatment
28th Jan 20227:00 amRNSHalf Year Results 2021-22
21st Jan 20227:00 amRNSPayment of Cash Dividend
20th Jan 20229:00 amRNSLicense to produce molnupiravir for COVID-19
30th Dec 202110:38 amRNSWorld's first generic version of Pfizer’s Paxlovid
24th Dec 20217:00 amRNSAnnual General Meeting Statement
8th Dec 20217:00 amRNSDelivery of COVID-19 vaccine doses
2nd Dec 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Nov 20217:43 amRNSStatement re: media comment
16th Nov 20217:00 amRNSNotice of AGM
11th Nov 202110:30 amRNSResults for First Quarter Ended 30 September 2021
9th Nov 20217:00 amRNSLaunch of world’s first generic molnupiravir
2nd Nov 20217:00 amRNSResults for the year ended 30 June 2021
21st Oct 202112:36 pmRNSNotification of Preliminary Results and AGM
11th Oct 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
1st Oct 20217:00 amRNSCompletion of Sanofi Bangladesh Acquisition
14th Sep 202110:20 amRNSSanofi Bangladesh Share Purchase Agreement signed
3rd Sep 20211:10 pmRNSAcquisition Approved by Bangladesh Bank
25th Aug 20216:01 pmRNSStatement re: media comment
26th Jul 20217:00 amRNSFDA approval for muscle relaxant drug Baclofen
7th Jul 20212:23 pmRNSUpdate on the supply of COVID-19 vaccine
30th Apr 20217:00 amRNSQ3 Financial Results
28th Apr 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Mar 20214:41 pmRNSSecond Price Monitoring Extn
24th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20212:06 pmRNSSecond Price Monitoring Extn
24th Mar 20212:00 pmRNSPrice Monitoring Extension
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
4th Feb 20217:34 amRNSUpdate on the supply of COVID-19 vaccine
28th Jan 20217:00 amRNSHalf Year Results 2020-21
22nd Jan 20217:00 amRNSPayment of Cash Dividend
21st Jan 20219:34 amRNSProposed acquisition of stake in Sanofi Bangladesh
18th Jan 20217:00 amRNSBoard Changes
14th Jan 20219:00 amRNSUpdate on the supply of COVID-19 vaccine
11th Jan 20217:00 amRNSStock Dividend Issued
11th Jan 20217:00 amRNSConfirmation of Board Changes
21st Dec 20207:00 amRNSAGM Statement
2nd Dec 202011:01 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.